Michael S. Schechter

Pediatric Pulmonology

1000 E Broad St
Richmond, VA 23219

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 105 publications

Health disparities in cystic fibrosis in the context of the exposome: recent developments and future directions.

Health disparities in cystic fibrosis in the context of the exposome: recent developments and future directions.

Journal: Expert review of respiratory medicine

Published: May 23, 2026

Obesity in adults with cystic fibrosis following prescription of elexacaftor/tezacaftor/ivacaftor.

Obesity in adults with cystic fibrosis following prescription of elexacaftor/tezacaftor/ivacaftor.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 04, 2026

Feasibility of tracking mental health in cystic fibrosis registries: lessons from current practice.

Feasibility of tracking mental health in cystic fibrosis registries: lessons from current practice.

Journal: Respiratory medicine

Published: December 09, 2025

The Human Cost of Respiratory Care: Professional Quality of Life and Burnout Across Multidisciplinary Cystic Fibrosis Teams.

The Human Cost of Respiratory Care: Professional Quality of Life and Burnout Across Multidisciplinary Cystic Fibrosis Teams.

Journal: Chest

Published: October 07, 2025

Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach Study.

Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach Study.

Journal: Annals of the American Thoracic Society

Published: September 08, 2025

Stakeholder Priorities for Cystic Fibrosis Mental Health Research: A Community and Provider Survey.

Stakeholder Priorities for Cystic Fibrosis Mental Health Research: A Community and Provider Survey.

Journal: Pediatric pulmonology

Published: July 26, 2025

Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) in People with Cystic Fibrosis in the United States.

Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) in People with Cystic Fibrosis in the United States.

Journal: Annals of the American Thoracic Society

Published: May 16, 2025

Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies after Rapid Adoption: A Dual-Approach Study.

Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies after Rapid Adoption: A Dual-Approach Study.

Journal: Annals of the American Thoracic Society

Published: March 04, 2025

Associations Between Socioeconomic Status and Adherence to Medications in People With Cystic Fibrosis.

Associations Between Socioeconomic Status and Adherence to Medications in People With Cystic Fibrosis.

Journal: Pediatric pulmonology

Published: February 25, 2025

Race, genetic ancestry, and socioeconomic status - a tangled web.

Race, genetic ancestry, and socioeconomic status - a tangled web.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 24, 2025

Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis.

Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: December 17, 2024

Cystic Fibrosis Learning Network Telehealth Innovation Lab During the COVID-19 Pandemic: Impact on Access to Care, Outcomes, and a New CF Care Model.

Cystic Fibrosis Learning Network Telehealth Innovation Lab During the COVID-19 Pandemic: Impact on Access to Care, Outcomes, and a New CF Care Model.

Journal: Pediatric pulmonology

Published: December 13, 2024

Showing 1-12 of 105

Last Updated: 09/26/2026